Abstract 478P
Background
NGS panels in oncology offer personalized therapies based on genomic alterations, but data on their clinical use and efficacy for non-glioblastoma CNS tumors is limited.
Methods
This study aimed to explore the molecular landscape of non-glioblastoma CNS tumors in patients (pts) who underwent FoundationOne®CDx between 11/2019 and 04/2023 at Veneto Institute of Oncology, Padua (Italy), while also assessing access to TT. Analysis was conducted on archival tumor, comprising a cohort of 176 pts. Brain tumors were classified per WHO 2021.
Results
Our cohort was constituted by: 19 Grade 2 IDH mut astrocytomas (A); 35 G3 IDH mut A; 34 G4 A; 29 oligodendrogliomas; 4 diffuse midline gliomas; 3 gangliogliomas; 3 pleomorphic xanthoA; 30 meningiomas; 4 medulloblastomas; 5 ependymomas; 2 neuroblastomas; 3 schwannomas; 4 pituitary adenomas; 1 hemangiopericytoma. The most frequent targettable molecular alterations (ESCAT ESMO Scale IIB-IIIB) were: PIK3CA/B mut (14.2%), NF1 and NF2 mut (10.2 and 13% respectively), BRCA 1-2 mut (8%), POLE mut (7.4%), high tumor mutational burden (TMB) (>10 mut/megabase) (6.8%), PDGFRA alterations (6.2%), BRAF non-V600E alterations (5.1%), RET and ROS1 mut (3.4 and 2.8% respectively), MDM2 amplification (2.3%), FGFR1-2-3 alterations and H3K28M (1.7%), MET amplification (1.7%), ALK rearrangements (1%). NTRK fusions and BRAF V600E have not been detected. 3/4 medulloblastomas pts exhibited a PTCH1 mutation. 4 pts received TT at recurrence, within clinical trials: one with grade 3 meningioma and ALK rearrangement treated with alectinib, one with PTCH1 mutant medulloblastoma treated with vismodegib, and two with high TMB treated with nivolumab/ipilumumab. Immune checkpoint inhib have shown remarkable activity in a meningioma patient, who is undergoing treatment for 12 months and has achieved a complete response according to RANO criteria, while another has had stable disease with alectinib for 7 months. In other cases TT did not demonstrate activity.
Conclusions
The incidence of targettable molecular alterations in adult CNS tumor pts was lower than in GBM. Nevertheless, in a few selected cases TT have the potential to increase treatment options at recurrence and improve outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Veneto Institute of Oncology IOV-IRCCS, Padua, Italy.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
547P - Artificial Intelligence-powered analysis of the tumor immune microenvironment in primary and metastatic colorectal cancer
Presenter: Elio Adib
Session: Poster session 16
548P - Simplified immune score based on CD8+ T-cells at the invasive margin provides comparable prognostic value to immune scores in non-metastatic colorectal cancer
Presenter: Durgesh Wankhede
Session: Poster session 16
549P - Combined morphometric immune signatures define the prognosis of patients with resectable colorectal liver metastases
Presenter: Markus Moehler
Session: Poster session 16
550P - The impact of mismatch repair status on accuracy of clinical staging in upfront resected stage II/III rectal cancer in the Netherlands
Presenter: Renee Lunenberg
Session: Poster session 16
551P - Efficacy prediction of chemoradiotherapy plus anti-PD-1/PD-L1 treatment by magnetic resonance imaging in MSS locally advanced rectal cancer
Presenter: Wentao Tang
Session: Poster session 16
552P - Baseline imaging biomarkers to predict outcomes in locally advanced colon cancer (LACC): Data from the FOxTROT international randomised-controlled trial
Presenter: James Platt
Session: Poster session 16
553P - Association of ctDNA-based MRD detection and MRD clearance with short-term overall survival in patients with resectable colorectal cancer: Updated analysis of CIRCULATE-Japan GALAXY
Presenter: JUN NAGATA
Session: Poster session 16
555P - Association between copy number aberration and ctDNA MRD in colorectal cancer: CIRCULATE-Japan GALAXY
Presenter: TOMOYA HARIMA
Session: Poster session 16